oteseconazole是一种口服给药的真菌CYP51抑制剂，在一年内使90%的女性免于复发。 复发性外阴阴道念珠菌病（RVVC，图片来源：cliniexpert.com） 2021年07月28 ...

A phase 3 randomized, double-blind, controlled trial has shown that oteseconazole (Mycovia Pharmaceuticals), an oral antifungal agent, is safe and effective in treating acute and recurrent yeast ...

Credit: Getty Images. Oteseconazole is a novel oral inhibitor of fungal CYP51. Topline results were announced from two phase 3 trials evaluating oteseconazole (VT-1161; Mycovia Pharmaceuticals ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

DURHAM, N.C.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) approved VIVJOA™ (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent ...

About VIVJOA™ VIVJOA™ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are ...

DURHAM – Mycovia Pharmaceuticals has submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for oteseconazole, an oral antifungal product for the ...

NDA supported by positive data from VIOLET and ultraVIOLET Phase 3 clinical trials evaluating oteseconazole in more than 870 women in 11 countries - - Oteseconazole’s Qualified Infectious Disease ...

If you continue to have this issue please contact [email protected]. Back to Healio Oteseconazole effectively treated recurrent vulvovaginal candidiasis and prevented acute episodes ...